Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Return on Sales (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Return on Sales for 8 consecutive years, with 0.36% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 333.0% year-over-year to 0.36%, compared with a TTM value of 0.78% through Dec 2025, up 525.0%, and an annual FY2025 reading of 0.78%, up 525.0% over the prior year.
  • Return on Sales was 0.36% for Q4 2025 at Zevra Therapeutics, up from 0.02% in the prior quarter.
  • Across five years, Return on Sales topped out at 2.88% in Q2 2025 and bottomed at 500.88% in Q2 2022.
  • Average Return on Sales over 5 years is 26.63%, with a median of 0.99% recorded in 2022.
  • The sharpest move saw Return on Sales tumbled -50139bps in 2022, then soared 50057bps in 2023.
  • Year by year, Return on Sales stood at 1.05% in 2021, then skyrocketed by 368bps to 2.8% in 2022, then crashed by -155bps to 1.54% in 2023, then plummeted by -93bps to 2.98% in 2024, then skyrocketed by 112bps to 0.36% in 2025.
  • Business Quant data shows Return on Sales for ZVRA at 0.36% in Q4 2025, 0.02% in Q3 2025, and 2.88% in Q2 2025.